Breaking News
Upgrade 0
📈 💰 Our AI knew ViaSat had strong potential… now it's up +99.7%
Pick Stocks with AI
Close

Novo Nordisk A/S Class B (NOVOb)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
358.8 0.0    0.00%
29/08 - Closed. Currency in DKK
Type:  Equity
Market:  Denmark
ISIN:  DK0062498333 
S/N:  3390128000
  • Volume: 5,222,178
  • Bid/Ask: 0.0 / 0.0
  • Day's Range: 353.7 - 360.1
Novo Nordisk B 358.8 0.0 0.00%

NOVOb Recent Sentiments

 
This page features our user's sentiments regarding the Novo Nordisk A/S Class B share. They are displayed on both charts of different time periods and in a detailed table.
BearishBullish
Start Date Username Call Open Rate End Date Chg. %
Aug 30, 2025 Marco Calza   358.8 0.00%
Aug 29, 2025 Juan Garcia Garcia   358.2 +0.17%
Aug 29, 2025 Antoine Lebeau   355.7 +0.87%
Aug 29, 2025 Laeto Gaudente   358.8 0.00%
Aug 28, 2025 IB IB   364.2 -1.48%
Aug 28, 2025 Daniele Donadello   362.8 -1.10%
Aug 28, 2025 罗 铃潼   363.8 -1.37%
Aug 28, 2025 Christiane Beck   356.7 +0.59%
Aug 28, 2025 Kaspars Ļaudups   361.8 -0.83%
Aug 28, 2025 Hans Alter   360.4 -0.44%
Aug 27, 2025 Kjell Norrby   359.3 -0.14%
Aug 27, 2025 Antoine Sylvain   358.7 +0.03%
Aug 27, 2025 Carlos Peña Solé   358.6 +0.06%
Aug 27, 2025 Diego Alejandro...   359.3 -0.14%
Aug 27, 2025 Marco Malatesta   351.0 +2.22%
Aug 26, 2025 Fredrik Lundberg   351.6 +2.05%
Aug 26, 2025 Johann Kupka   352.0 +1.93%
Aug 26, 2025 Pierangelo Dell Acqua   354.2 +1.30%
Aug 26, 2025 Andy Cardenas García   360.1 -0.36%
Aug 26, 2025 Javier Guarnerio   367.3 -2.31%
Aug 26, 2025 stefano ghione   361.0 -0.61%
Aug 26, 2025 Timo Kronlöf   360.3 -0.42%
Aug 26, 2025 Teemu Makkonen   360.6 +0.50%
Aug 26, 2025 Jose Alonso   359.2 -0.11%
Aug 26, 2025 Miska Berg   359.8 -0.28%
Aug 26, 2025 Luis Prados   359.4 -0.17%
Aug 26, 2025 jonas Hansen   358.0 +0.22%
Aug 26, 2025 Jelena Sladzevskis   358.1 +0.20%
Aug 26, 2025 Jürgen M   357.9 +0.25%
Aug 26, 2025 Dennis Neumeyer   359.4 -0.17%
Aug 25, 2025 sante Cogliandro   366.8 -2.18%
Aug 25, 2025 Torben Lundqvist   365.0 -1.70%
Aug 25, 2025 victor ceuppens   365.0 -1.70%
Aug 25, 2025 Jose H   364.2 -1.48%
Aug 25, 2025 Marco Calza   363.9 Aug 25, 2025 @ 367.3 +0.93%
Aug 25, 2025 Dmitrii Iascov   363.9 Aug 25, 2025 @ 367.3 +0.93%
Aug 25, 2025 Stefán Ómar van Hagen   363.9 Aug 25, 2025 @ 367.3 +0.93%
Aug 25, 2025 Electo Pavía   363.9 Aug 25, 2025 @ 367.3 +0.93%
Aug 25, 2025 Pedro Pisano   364.4 +1.54%
Aug 25, 2025 Rasmus Brøndsel   362.7 -1.08%
Aug 23, 2025 Barbadillo Villanueva   363.9 Aug 25, 2025 @ 367.3 +0.93%
Aug 22, 2025 Rosaria Federico   366.3 Aug 26, 2025 @ 350.7 -4.26%
Aug 22, 2025 Cristobal Ruiz   366.4 Aug 25, 2025 @ 367.3 +0.25%
Aug 22, 2025 Bart Vansteelandt   364.8 -1.64%
Aug 22, 2025 Big T   368.2 -2.55%
Aug 22, 2025 Rom Ant   367.7 -2.42%
Aug 22, 2025 Ahmed Hachimi   367.5 -2.37%
Aug 22, 2025 Giuseppe Fontana   365.8 Aug 25, 2025 @ 367.3 +0.41%
Aug 22, 2025 Oscar de Sola   363.9 Aug 25, 2025 @ 367.3 +0.93%
Aug 22, 2025 Dominique ARANDA   356.1 Aug 25, 2025 @ 367.3 -3.15%
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

NOVOb Comments

Write your thoughts about Novo Nordisk A/S Class B
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email